On February 25, an enterprise survey of the App showed that the Intellectual Property Tribunal of the Supreme People's Court was scheduled to open a public hearing at 9:30 a.m. on February 26, 2025 in the seventh court of the Intellectual Property Tribunal of the Supreme People's Court to hear the appellant Boehringer Ingelheim International Co., Ltd. (hereinafter referred to as "Boehringer Ingelheim", BI), the appellee China National Intellectual Property Administration, the third person in the first instance Jiangsu Haosen Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Jiangsu Haosen"), Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. (hereinafter referred to as "Sichuan Kelun"), Zhengda Tianqing Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Zhengda Tianqing"), and Jiangsu Wanbang The case of administrative dispute over the invalidation of invention patent rights of Biochemical Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Jiangsu Wanbang") and Hangzhou Sino American East China Pharmaceutical Co., Ltd. (hereinafter referred to as "Sino American East China").

Time Finance learned from Huadong Pharmaceutical (000963. SZ) that the case is related to the patent invalidation of the anti diabetic star drug empagliflozin (trade name: Jardiance/Outangjing), and the above case is currently in the second instance trial.

Huadong Pharmaceutical told Time Finance that the original expiration date of the patent for empagliflozin compound was March 2025. In 2020, the compound patents of Engelgin were declared invalid in China by the China National Intellectual Property Administration. Later, the original pharmaceutical enterprise filed an administrative lawsuit with the Beijing Intellectual Property Court. The first instance of the case in 2023 was judged as "rejecting the plaintiff's lawsuit".

Zhongmei Huadong (a subsidiary of Huadong Pharmaceutical Holdings) serves as a third party and is not the defendant, "Huadong Pharmaceutical emphasized. The company expects that this case and its final outcome will not have a significant impact on the company.

On the same day, Time Finance sent an interview outline to Boehringer Ingelheim regarding the expected outcome of the second trial and the company's future innovative drug research and patent layout strategy in the Chinese market. As of the time of writing, no response has been received.